Serina Therapeutics (Al), Inc.

Randall W Moreadith

Michael David Bentley

J Milton Harris

Zhihao Fang

Tacey Viegas

Kunsang Yoon

Rebecca Weimer

The present disclosure provides for polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer. Methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions comprising a POZ conjugate are also provided.

Polyoxazoline-drug conjugates with novel pharmacokinetic properties

Polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer and methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions including a POZ conjugate are also provided.

Growing community of inventors

Huntsville, AL, United States of America

Randall W Moreadith